Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Clinical Chemistry
Emerging Technology
Immunoassays
Molecular Diagnostics
Pathology & AI
Liquid Biopsy
AI-driven liquid biopsy method predicts cancer recurrence
By
LabPulse.com staff writers
An artificial intelligence (AI)-guided approach for detecting tumor DNA in blood has shown remarkable sensitivity in predicting cancer recurrence, according to a study published in
Nature
.
June 17, 2024
Karius gets FDA breakthrough device designation for infectious disease test
By
LabPulse.com staff writers
Karius announced today that its Karius Test for the diagnosis and management of lung infections in immunocompromised patients has been granted breakthrough device designation from the FDA.
May 16, 2024
Karius raises $100M in series C funding
By
LabPulse.com staff writers
Diagnostics firm Karius has secured $100 million in series C funding in a recent financing round.
May 6, 2024
High hopes for accurate blood test detecting malignant brain tumors
By
Matt Limb
A simple blood test to detect malignant brain tumors that can be hard to locate could spare many cancer patients risky and invasive surgery, say scientists.
February 9, 2024
Illumina unveils new version of liquid biopsy assay
By
Matt Limb
Genomics company Illumina has announced a new generation of its distributed liquid biopsy assay for the genomic profiling of solid tumors.
November 8, 2023
Sophia Genetics, AstraZeneca, Memorial Sloan Kettering to collaborate on cancer test access
By
LabPulse.com staff writers
Sophia Genetics is collaborating with Memorial Sloan Kettering (MSK) Cancer Center and AstraZeneca to expand MSK's genomic sequencing tests to a global scale, with the aim of by providing more inclusive access to cancer testing worldwide.
October 20, 2023
AMP publishes best-practice recommendations for ctDNA assays
By
LabPulse.com staff writers
The Association for Molecular Pathology (AMP) has published its best-practice recommendations for validating, reporting, and publishing clinical circulating tumor DNA (ctDNA) assays.
October 17, 2023
Agilent to sell Resolution Bioscience to Exact Sciences
By
LabPulse.com staff writers
Agilent Technologies has announced that it is selling Resolution Bioscience, its cancer testing business, to Exact Sciences for an undisclosed sum.
September 12, 2023
Agilent closes $550M liquid biopsy unit after failing to find path to profits
By
Nick Paul Taylor
When Agilent bought Resolution, it identified the company’s presence in fast-growing NGS technologies for precision oncology as a way to expand its addressable market; rather than realizing that opportunity, Agilent has ended up cutting its losses.
August 18, 2023
Cancer detection firm Elypta awarded quality certification
By
LabPulse.com staff writers
The scope of the certification includes the design and development of in vitro diagnostic (IVD) test kits and software for Elypta’s liquid biopsy-based platform for the detection and measurement of glycosaminoglycans (GAGomes) across different cancers.
July 7, 2023
Quest Diagnostics completes acquisition of Haystack Oncology, adds MRD liquid biopsy to Dx portfolio
By
LabPulse.com staff writers
Quest expects next year to use the MRD technology in blood-based clinical lab testing services for solid tumor cancers.
June 21, 2023
Myriad Genetics, MD Anderson collaborate on metastatic renal cell carcinoma research
By
LabPulse.com staff writers
The project will use Myriad’s minimal residual disease testing platform, a tumor-informed high-definition assay that detects circulating tumor DNA.
June 12, 2023
Page 1 of 4
Next Page